---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-126639"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:29:01.846397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GSBR-1290 Phase 2a meets endpoints; significant HbA1c and weight reductions in T2DM and obesity

## Summary
- HbA1c reduction: -1.01% to -1.02% placebo-adjusted at Week 12 (p≤0.008).
- Weight loss: T2DM -3.26% to -3.51% placebo-adjusted at Week 12; obesity -4.74% at Week 8 (p<0.0001).
- No treatment-related SAEs; 2.8% discontinuation rate due to AEs; GI events most common.
- Full 12-week obesity data expected Q2 2024; Phase 2b obesity study to start H2 2024.
- Toxicology studies show >100-fold safety margin; Japanese bridging study supports global plans.

## SEC filing metadata
- accession: 0001104659-23-126639
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/0001104659-23-126639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923126639/tm2329572d16_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-126639
- JSON: https://secwatch.observer/filing/0001104659-23-126639.json
- Plain text: https://secwatch.observer/filing/0001104659-23-126639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.